These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 37894951)

  • 1. Gut Microbiota Patterns in Patients with Non-Alcoholic Fatty Liver Disease: A Comprehensive Assessment Using Three Analysis Methods.
    Korobeinikova AV; Zlobovskaya OA; Sheptulina AF; Ashniev GA; Bobrova MM; Yafarova AA; Akasheva DU; Kabieva SS; Bakoev SY; Zagaynova AV; Lukashina MV; Abramov IA; Pokrovskaya MS; Doludin YV; Tolkacheva LR; Kurnosov AS; Zyatenkova EV; Lavrenova EA; Efimova IA; Glazunova EV; Kiselev AR; Shipulin GA; Kontsevaya AV; Keskinov AA; Yudin VS; Makarov VV; Drapkina OM; Yudin SM
    Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37894951
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phenotyping non-alcoholic fatty liver disease by the gut microbiota: Ready for prime time?
    Demir M; Lang S; Martin A; Farowski F; Wisplinghoff H; Vehreschild MJGT; Krawczyk M; Nowag A; Scholz CJ; Kretzschmar A; Roderburg C; Lammert F; Goeser T; Kasper P; Steffen HM
    J Gastroenterol Hepatol; 2020 Nov; 35(11):1969-1977. PubMed ID: 32267559
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Understanding the Role of the Gut Microbiome and Microbial Metabolites in Non-Alcoholic Fatty Liver Disease: Current Evidence and Perspectives.
    Vallianou N; Christodoulatos GS; Karampela I; Tsilingiris D; Magkos F; Stratigou T; Kounatidis D; Dalamaga M
    Biomolecules; 2021 Dec; 12(1):. PubMed ID: 35053205
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metagenomic identification of gut microbiota distribution on the colonic mucosal biopsy samples in patients with non-alcoholic fatty liver disease.
    Delik A; Dinçer S; Ülger Y; Akkız H; Karaoğullarından Ü
    Gene; 2022 Jul; 833():146587. PubMed ID: 35598686
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prediction of advanced fibrosis in non-alcoholic fatty liver disease using gut microbiota-based approaches compared with simple non-invasive tools.
    Lang S; Farowski F; Martin A; Wisplinghoff H; Vehreschild MJGT; Krawczyk M; Nowag A; Kretzschmar A; Scholz C; Kasper P; Roderburg C; Lammert F; Goeser T; Steffen HM; Demir M
    Sci Rep; 2020 Jun; 10(1):9385. PubMed ID: 32523101
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Longitudinal 16S rRNA Sequencing Reveals Relationships among Alterations of Gut Microbiota and Nonalcoholic Fatty Liver Disease Progression in Mice.
    Zhuge A; Li S; Lou P; Wu W; Wang K; Yuan Y; Xia J; Li B; Li L
    Microbiol Spectr; 2022 Jun; 10(3):e0004722. PubMed ID: 35647690
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bile acids associate with specific gut microbiota, low-level alcohol consumption and liver fibrosis in patients with non-alcoholic fatty liver disease.
    Adams LA; Wang Z; Liddle C; Melton PE; Ariff A; Chandraratna H; Tan J; Ching H; Coulter S; de Boer B; Christophersen CT; O'Sullivan TA; Morrison M; Jeffrey GP
    Liver Int; 2020 Jun; 40(6):1356-1365. PubMed ID: 32243703
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A High-Fat Diet Increases the Characteristics of Gut Microbial Composition and the Intestinal Damage Associated with Non-Alcoholic Fatty Liver Disease.
    Zhu X; Cai J; Wang Y; Liu X; Chen X; Wang H; Wu Z; Bao W; Fan H; Wu S
    Int J Mol Sci; 2023 Nov; 24(23):. PubMed ID: 38069055
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gut microbiota dysbiosis in patients with non-alcoholic fatty liver disease.
    Shen F; Zheng RD; Sun XQ; Ding WJ; Wang XY; Fan JG
    Hepatobiliary Pancreat Dis Int; 2017 Aug; 16(4):375-381. PubMed ID: 28823367
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota.
    Boursier J; Mueller O; Barret M; Machado M; Fizanne L; Araujo-Perez F; Guy CD; Seed PC; Rawls JF; David LA; Hunault G; Oberti F; Calès P; Diehl AM
    Hepatology; 2016 Mar; 63(3):764-75. PubMed ID: 26600078
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gut Microbiota Profile Changes in Patients with Inflammatory Bowel Disease and Non-Alcoholic Fatty Liver Disease: A Metagenomic Study.
    De Caro C; Spagnuolo R; Quirino A; Mazza E; Carrabetta F; Maurotti S; Cosco C; Bennardo F; Roberti R; Russo E; Giudice A; Pujia A; Doldo P; Matera G; Marascio N
    Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791490
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gut microbiome features and metabolites in non-alcoholic fatty liver disease among community-dwelling middle-aged and older adults.
    Zeng F; Su X; Liang X; Liao M; Zhong H; Xu J; Gou W; Zhang X; Shen L; Zheng JS; Chen YM
    BMC Med; 2024 Mar; 22(1):104. PubMed ID: 38454425
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interactions between the cecal microbiota and non-alcoholic steatohepatitis using laying hens as the model.
    Hamid H; Zhang JY; Li WX; Liu C; Li ML; Zhao LH; Ji C; Ma QG
    Poult Sci; 2019 Jun; 98(6):2509-2521. PubMed ID: 30690636
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design and rationale of the INSYTE study: A randomised, placebo controlled study to test the efficacy of a synbiotic on liver fat, disease biomarkers and intestinal microbiota in non-alcoholic fatty liver disease.
    Scorletti E; Afolabi PR; Miles EA; Smith DE; Almehmadi A; Alshathry A; Moyses HE; Clough GF; Wright M; Patel J; Bindels L; Delzenne NM; Calder PC; Byrne CD
    Contemp Clin Trials; 2018 Aug; 71():113-123. PubMed ID: 29787859
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Microbial Intervention as a Novel Target in Treatment of Non-Alcoholic Fatty Liver Disease Progression.
    Zhou Y; Zheng T; Chen H; Li Y; Huang H; Chen W; Du Y; He J; Li Y; Cao J; Nie Y; Zhou Y
    Cell Physiol Biochem; 2018; 51(5):2123-2135. PubMed ID: 30522122
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ileal Bile Acid Transporter Inhibitor Improves Hepatic Steatosis by Ameliorating Gut Microbiota Dysbiosis in NAFLD Model Mice.
    Matsui M; Fukunishi S; Nakano T; Ueno T; Higuchi K; Asai A
    mBio; 2021 Aug; 12(4):e0115521. PubMed ID: 34225483
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protective effect of quercetin on high-fat diet-induced non-alcoholic fatty liver disease in mice is mediated by modulating intestinal microbiota imbalance and related gut-liver axis activation.
    Porras D; Nistal E; Martínez-Flórez S; Pisonero-Vaquero S; Olcoz JL; Jover R; González-Gallego J; García-Mediavilla MV; Sánchez-Campos S
    Free Radic Biol Med; 2017 Jan; 102():188-202. PubMed ID: 27890642
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Distinct signatures of gut microbiome and metabolites associated with significant fibrosis in non-obese NAFLD.
    Lee G; You HJ; Bajaj JS; Joo SK; Yu J; Park S; Kang H; Park JH; Kim JH; Lee DH; Lee S; Kim W; Ko G
    Nat Commun; 2020 Oct; 11(1):4982. PubMed ID: 33020474
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Qushi Huayu decoction ameliorates non-alcoholic fatty liver disease in rats by modulating gut microbiota and serum lipids.
    Ni Y; Wang X; Wu Q; Yao Y; Xu Y; Li Y; Feng Q; Zhou M; Gou X
    Front Endocrinol (Lausanne); 2023; 14():1272214. PubMed ID: 37900123
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    Riezu-Boj JI; Barajas M; Pérez-Sánchez T; Pajares MJ; Araña M; Milagro FI; Urtasun R
    Nutrients; 2022 Dec; 14(24):. PubMed ID: 36558371
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.